Feasibility of using maternal cancer screening visits to identify adolescent girls eligible for human papillomavirus vaccination
- PMID: 21054184
- PMCID: PMC2990278
- DOI: 10.1089/jwh.2010.1959
Feasibility of using maternal cancer screening visits to identify adolescent girls eligible for human papillomavirus vaccination
Abstract
Purpose: Breast or cervical cancer screening visits may present an opportunity to motivate mothers to have their daughters vaccinated against human papillomavirus (HPV). In preparation for a future intervention study, we sought to establish the feasibility of using these visits to identify women with at least one daughter in the appropriate age range for adolescent HPV vaccination.
Methods: We conducted a cross-sectional mailed survey of women who had received breast or cervical cancer screening within the 6-18 months before the survey. The study was conducted at two diverse institutions: one serving a mostly black (54.1%) urban inner-city population and another serving a mostly white (87.5%) suburban population.
Results: Our overall response rate was 28% (n = 556) in the urban site and 38% (n = 381) in the suburban site. In the urban site, the proportions of mothers completing mammography or Pap smear visits with HPV vaccine-eligible daughters were 23% and 24%, respectively. In the suburban site, the proportions of mothers completing mammography or Pap smear with at least one vaccine-eligible daughter were 41% and 26%, respectively.
Conclusions: Women who undergo breast or cervical cancer screening in the two different demographic groups evaluated have at least one adolescent daughter at the appropriate age for HPV vaccination. An important implication of this finding in adolescent daughters of urban mothers is the potential use of maternal breast or cervical cancer screening encounters to target a potentially undervaccinated group.
Figures
Similar articles
-
Appraisal of willingness to vaccinate daughters with human papilloma virus vaccine and cervical cancer screening uptake among mothers of adolescent students in Abakaliki, Nigeria.Niger J Clin Pract. 2019 Sep;22(9):1286-1291. doi: 10.4103/njcp.njcp_452_18. Niger J Clin Pract. 2019. PMID: 31489868
-
National patterns in human papillomavirus vaccination: an analysis of the National Survey of Family Growth.Hum Vaccin Immunother. 2012 Feb;8(2):234-42. doi: 10.4161/hv.18456. Epub 2012 Feb 1. Hum Vaccin Immunother. 2012. PMID: 22414967
-
Black mother's intention to vaccinate daughters against HPV: A mixed methods approach to identify opportunities for targeted communication.Gynecol Oncol. 2018 Jun;149(3):506-512. doi: 10.1016/j.ygyno.2018.03.047. Epub 2018 Mar 24. Gynecol Oncol. 2018. PMID: 29588103 Free PMC article.
-
Association between maternal preventive care utilization and adolescent vaccination: it's not just about Pap testing.J Pediatr Adolesc Gynecol. 2014 Feb;27(1):29-36. doi: 10.1016/j.jpag.2013.08.012. Epub 2013 Dec 4. J Pediatr Adolesc Gynecol. 2014. PMID: 24315716
-
A designathon to co-create HPV screening and vaccination approaches for mothers and daughters in Nigeria: findings from a community-led participatory event.BMC Infect Dis. 2024 Jun 20;24(1):606. doi: 10.1186/s12879-024-09479-7. BMC Infect Dis. 2024. PMID: 38902607 Free PMC article.
References
-
- Parkin DM. Cancer in developing countries. Cancer Surv. 1994;19–20:519–561. - PubMed
-
- Womack SD. Chirenje ZM. Blumenthal PD, et al. Evaluation of a human papillomavirus assay in cervical screening in Zimbabwe. Br J Obstet Gynaecol. 2000;107:33–38. - PubMed
-
- Jemal A. Siegel R. Ward E, et al. Cancer statistics, 2006. CA Cancer J Clin. 2006;56:106–130. - PubMed
-
- Insinga RP. Dasbach EJ. Elbasha EH. Assessing the annual economic burden of preventing and treating anogenital human papillomavirus-related disease in the U.S.: Analytic framework and review of the literature. Pharmacoeconomics. 2005;23:1107–1122. - PubMed
-
- U.S. Food and Drug Administration. FDA approves new vaccine for prevention of cervical cancer. 2009. www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2009/ucm187048.htm. www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2009/ucm187048.htm
